ASCO 2020: PD-1 mono-anti-Opdivo, CTLA-4 mono-Yervoy combination chemotherapy first-line treatment of non-small cell lung cancer, reducing risk of death by 31%

Bristol Myers Squibb announced the detailed results of its CheckMate-9LA trial, which showed that the use of PD-1 mono-anti-Opdivo (nivolumab) and CTLA-1 mono-resistant Yervoy (ipilimumab) chemotherapy as a first-line treatment for metastatic non-small cell lung cancer (NSCLC) patients reduced the risk of death by 31% compared to individual chemotherapyThe company announced last year that the study had reached its main endpoint of overall survival (OS)in this trial, patients with metastatic NSCLC, regardless of PD-L1 expression and histology, were randomly assigned to receive Opdivo plus Yervoy combined chemotherapy or simple chemotherapy as a first-line treatmentThe main endpoints of the study were OS, and the secondary endpoints were Progressless Lifetime (PFS) and Overall Mitigation Rate (ORR)results showed that the combination of Opdivo and Yervoy and chemotherapy showed continued improvement in OS, with a median OS of 10.9 months and 15.6 months, respectively, compared to chemotherapy aloneThe BMS noted that, regardless of PD-L1 expression levels, Opdivo and Yervoy combined chemotherapy improved OS in patients, reducing the risk of death by 38 percent in patients with PD-L1 of less than 1 percent, and reducing the risk of death in patients with PD-L1 by at least 1 percent by 36 percent, a combination of double immunotherapy and chemotherapy showed a one-year PFS of 33 percent, compared with 18 percent for chemotherapy, 38 percent for ORR and 25 percent for chemotherapy alonethe current combination of PD-1 monoopo and CTLA-4 monoantigen Yervoy has been approved for use in a variety of tumors, including for the treatment of non-reprecision or metastatic melanoma, specific types of advanced renal cell carcinoma and hepatocellular carcinoma